Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Greenwich Lifesciences Inc GLSI

Healthcare Biotechnology
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a... see more

Recent & Breaking News (NDAQ:GLSI)

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Business Wire April 20, 2022

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Business Wire April 19, 2022

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Business Wire March 3, 2022

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Business Wire February 3, 2022

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Business Wire February 1, 2022

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Business Wire January 24, 2022

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Business Wire December 15, 2021

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Business Wire December 9, 2021

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Business Wire December 8, 2021

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Business Wire December 7, 2021

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Business Wire December 6, 2021

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Business Wire November 18, 2021

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

Business Wire November 17, 2021

Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

Business Wire November 11, 2021

Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Business Wire November 10, 2021

Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts

Business Wire November 9, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI

Newsfile October 20, 2021

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

Business Wire September 28, 2021

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference

Business Wire September 27, 2021

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

Business Wire September 23, 2021